MedTrace Logo

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

NCT00003398 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2019-10-17

No results posted yet for this study

Summary

RATIONALE: Bone marrow that has been treated to remove certain white blood cells may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy, and may reduce the chance of developing graft-versus-host disease following bone marrow transplantation.

PURPOSE: Phase IV trial to study the incidence of graft-versus-host disease in patients who have hematologic cancer and who are undergoing bone marrow transplantation from a donor.

Conditions

Interventions

BIOLOGICAL

anti-thymocyte globulin

BIOLOGICAL

filgrastim

DRUG

cyclophosphamide

DRUG

thiotepa

PROCEDURE

allogeneic bone marrow transplantation

PROCEDURE

bone marrow ablation with stem cell support

RADIATION

radiation therapy

Sponsors & Collaborators

  • University of Maryland Greenebaum Cancer Center

    collaborator OTHER

  • University of Maryland, Baltimore

    lead OTHER

Principal Investigators

  • Barry R. Meisenberg, MD · University of Maryland Greenebaum Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-09-30
Primary Completion
2000-05-31
Completion
2000-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003398 on ClinicalTrials.gov